TransMedics Group, Inc.

TMDX Nasdaq SEC CIK 1756262
Follow TransMedics Weekly email: filings, results

Financials

Reported figures only · latest: Q3 2026 USD · US GAAP
Revenue, last quarter $203M +41.1% vs same quarter last year
Net income $17.1M −29.8% vs same quarter last year
EPS, diluted $0.46 −30.3% vs same quarter last year
Operating cash flow $36M −48.3% vs same quarter last year
Revenue by quarter
$121.6M
$143.5M
$157.4M
$143.8M
$160.8M
$173.9M
$189.9M
$203M
Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26 Q3 26

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, US GAAP
Revenue and net income9 fiscal years
  • Revenue
  • Net income
−$200M$0$200M$400M$600M$800MFY17FY18FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearRevenueNet income
FY25$605.5M$190.3M
FY24$441.5M$35.5M
FY23$241.6M−$25M
FY22$93.5M−$36.2M
FY21$31.4M−$44.2M
FY20$28.4M−$28.7M
FY19$25.8M−$33.5M
FY18$14.7M−$23.8M
FY17--
MarginsShare of revenue
  • Gross margin
  • Operating margin
  • Net margin
−200%−100%0%100%FY17FY18FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearGross marginOperating marginNet margin
FY2559.9%17.9%31.4%
FY2459.4%8.5%8%
FY2363.8%−11.9%−10.3%
FY2269.8%−33.6%−38.7%
FY2167.4%−125.6%−140.8%
FY2058.7%−93%−101.4%
FY1953.6%−114.5%−129.8%
FY1839.1%−138.1%−162.1%
FY17---
Free cash flowOperating cash flow minus capital expenditure
−$200M−$100M$0$100M$200MFY17FY18FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearFree cash flow
FY25$133.6M
FY24−$80.9M
FY23−$164.9M
FY22−$57.7M
FY21−$32.4M
FY20−$30.7M
FY19−$32.5M
FY18−$26.4M
FY17-
Net margin vs the sectorMedian of Healthcare companies filing with the SEC
  • TransMedics
  • Healthcare median
−200%−150%−100%−50%0%50%FY17FY18FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearTransMedicsHealthcare median
FY2531.4%−30.8%
FY248%−47%
FY23−10.3%−58%
FY22−38.7%−80.4%
FY21−140.8%−71.9%
FY20−101.4%−62.2%
FY19−129.8%−46.3%
FY18−162.1%−49.6%
FY17-−45.9%